Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Long term it probably means nothing
No the market seems to just yawn
This is a couple guys who control some ip and have a big office in a city where neither of them live.
Need another partner for a larger indication
It could be a pivotal week for RVX. Loan resolution is due and of course the top line could also be this week
ProMIS near-term goal is partnering in 3-12 months. The current presentation is here:
https://promisneurosciences.com/wp-content/uploads/2019/09/ProMIS.-Corporate.OV_.-HCW.2019-1.pdf
Correlation is clear. Causal proof still somewhat lacking. Is this just bad luck?
I will take a look
I’m still happy I added a while back. May add more of we get a few more up days on some volume
Oncology trials take forever. In the meantime, price fluctuates. Doesn’t mean Marker is any more of a target than anyone else.
Not sure if you folks have that much influence but there most certainly has been a correlation. Ha!
Yes ... should be an update on clinical plans soon.
One day rally
should be the 3rd highest volume day in the past year.
Seems like a run up to the nda
It is time for an update on clinical progress.
No real volume but some nice gains of late.
it is worth watching if only for that purpose
Prurisol is worth at least $10Billion.
Thank you. I held a few for the recent little pop and am out again at the moment
Does the SEC still exist? I thought all became anarchy.
They have about 12 months at the current burn rate...but will need to raise in probably 3-6 months so things don't get cut too close.
They seem to have something here, however, and that means things could run up fast.
It seems to be starting the past few days, and volume has come with it.
This is from page 13 of the 10Q and sounds about as good as possible. Why is the price at 22 cents?
"Safety and feasibility data from the first 38 patients enrolled on the SIERRA trial, which represents twenty five percent of the total of 150 patients to be enrolled in the trial, was presented in an oral presentation at the American Society of Hematology (“ASH”) Annual Meeting in December 2018 and in a late breaking oral presentation at the Transplantation and Cellular Therapy (“TCT”) Annual Meeting in February 2019. It was reported that all patients initially randomized to the study arm that received a therapeutic dose of Iomab-B (18/18) received a BMT, with a median time to BMT of 28 days, and all patients achieved engraftment in a median time of 16 days despite a high median blast count of 30%. On the control arm, 4/19 patients received a BMT after receiving conventional care with a median time to BMT of 67 days and median blast count of 26%. Of the patients failing to achieve a CR with conventional care (15/19), 10 patients were eligible to cross over to the study arm. All cross over patients (10/10) received a BMT after receiving Iomab-B, with a median time to BMT of 66 days and all patients achieved engraftment in a median time of 17 days despite high median blast count of 45% at time of cross over. There was no (0/18) 100-day non-relapse mortality reported in the Iomab-B arm, while 1 of 4 patients in the control arm and 1 of 10 cross over patients experienced 100-day non-relapse mortality. In addition, single-agent activity of Iomab-B in the first twenty five percent of patients in the SIERRA trial was presented at ASCO or the American Society of Clinical Oncology annual Meeting in June 2019. A strong anti-leukemic effect was observed from single agent Iomab-B in the 16 patients for whom data was available with a median reduction in peripheral blasts by day 3 following Iomab-B administration of 98% and 100% by day 8, prior to any other pre-BMT conditioning. Clearance of peripheral blasts is necessary for BMT to be successful and has been reported as being an independent prognostic marker that is predictive of both Complete Response and Relapse-Free Survival."
ProMIS Neurosciences Announces Second Quarter 2019 Results
PR NEWSWIRE 6:30 AM ET 8/13/2019
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease
TORONTO and CAMBRIDGE, MA, Aug. 13, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc.(ARFXF) , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2019.
"Over the course of the first half of 2019, the breadth and depth of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities in neurodegenerative diseases," stated Eugene Williams, ProMIS' Executive Chairman. "In the second quarter of this year, we were able to identify novel antibodies for Alzheimer's disease (AD) with selectivity for the neurotoxic form of tau. This is in addition to the prior identification of antibody candidates selectively targeting toxic forms of alpha-synuclein (a-syn) for Parkinson's disease (PD) and toxic, aggregated forms of TDP43 for amyotrophic lateral sclerosis (ALS)."
Corporate Highlights
In June 2019, the Company completed a private placement of 4,680,000 common share units at a price of $0.25 per unit resulting in gross proceeds of approximately $1,170,000 ($1,093,492 net of share issuance costs). Each unit consisted of one common share and one common share warrant. The common shares are subject to a four-month hold period from the date of issuance. Each warrant is exercisable into one common share at a price of $0.35 per share at any time for five years.
In May 2019, ProMIS announced the identification of novel antibodies for AD with selectivity for the neurotoxic form of tau. ProMIS leveraged its proprietary drug discovery and development platform to identify several novel antibodies that selectively bind toxic oligomers of tau. The platform produced antibodies that meet a key success factor for a viable Alzheimer's disease therapy: the ability to selectively target the neurotoxic form of a protein, while sparing the normal forms of the protein, a challenge that has contributed to recent late-stage clinical trial failures. The platform not only generates high-quality antibody candidates, it delivers powerful, validated candidates in months versus years. Used in combination with new biomarkers for Alzheimer's disease, researchers could dramatically improve the success and speed of future therapy development efforts.
In June 2019, ProMIS presented key data on monoclonal antibody PMN310 for AD at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world's most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care. ProMIS Chief Development Officer Dr. Johanne Kaplan presented data showing that PMN310 possesses superior selectivity for amyloid beta toxic oligomers and improved therapeutic potential compared with other amyloid beta-directed antibodies.
Scientific Advisory Board Appointment
In June 2019, the Company appointed C. Warren Olanow, MD, FRCPC, FAAN, FRCP(Hon) to its scientific advisory board (SAB). Dr. Olanow has dedicated his career to the study of neurodegeneration, particularly Parkinson's disease, through his work in academia, scientific research, clinical trials and professional societies. He is the previous Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology at the Mount Sinai School of Medicine in New York City and is presently Professor Emeritus in the Department of Neurology and in the Department of Neuroscience. He also serves as Chief Executive Officer of CLINTREX, a pharmaceutical advisory firm that has designed numerous clinical trials in neurodegenerative disease for the pharmaceutical industry.
Financial Results
Results of Operations – Three months ended June 30, 2019 and 2018
Net loss for the three months ended June 30, 2019 was $1,858,530, compared to a net loss of $2,214,861 for the three months ended June 30, 2018, respectively. Included in the net loss amount for the three months ended June 30, 2019 were non-cash expenses of $153,461, representing share-based compensation and amortization of an intangible asset, compared to $173,544 for the three months ended June 30, 2018. The decrease in the net loss in the three months ended June 30, 2019 reflects a decrease in costs associated with external contract research organizations for internal programs, patent costs and share-based compensation offset by increased consultant salaries and associated costs and general corporate expenditures.
Research and development expenses for the three months ended June 30, 2019 were $1,042,618, as compared to $1,531,075 in the three months ended June 30, 2018. The decrease in research and development expense for the three months ended June 30, 2019 is primarily attributed to decreased costs associated external contract research organizations for internal programs and patent costs offset by higher contracted research salaries and associated costs, and higher share-based compensation.
General and administrative expenses for the three months ended June 30, 2019 were $815,937, as compared to $683,786 in the three months ended June 30, 2018. The increase in general and administrative expense for the three months ended June 30, 2019 is primarily attributable to increased consultant salaries and associated costs and general corporate expenditures offset by decreased share-based compensation.
Results of Operations – Six months ended June 30, 2019 and 2018
Net loss for the six months ended June 30, 2019 was $4,305,107, compared to a net loss of $3,771,733 for the six months ended June 30, 2018, respectively. Included in the net loss amount for the six months ended June 30, 2019 were non-cash expenses of $417,334, representing share-based compensation and amortization of an intangible asset, compared to $502,555 for the six months ended June 30, 2018. The increase in the net loss in the six months ended June 30, 2019 reflects the costs associated with operating the Company's AD therapeutics program, increased contracted research and consultant salaries and associated costs and general corporate expenditures.
Research and development expenses for the six months ended June 30, 2019 were $2,813,271, as compared to $2,229,082 in the six months ended June 30, 2018. The increase in research and development expense for the six months ended June 30, 2019 is primarily attributed to increased spending on external contract research organizations for internal programs, higher contracted research salaries and associated costs, and higher share-based compensation offset by reduced patent costs.
General and administrative expenses for the six months ended June 30, 2019 were $1,491,861, as compared to $1,542,656 in the six months ended June 30, 2018. The decrease in general and administrative expense for the six months ended June 30, 2019 is primarily attributable to decreased share-based compensation offset by increased consultant salaries and associated costs, general corporate expenditures and foreign exchange.
Outlook
The Company will continue to build on its unique, proprietary discovery and development platform to further characterize the potential benefits of its programs selectively targeting toxic aggregates of TDP43 and SOD1 in ALS, toxic forms of a-syn in PD and other a-syn-related disorders, and toxic forms of tau and amyloid beta in AD and other dementias to further support ongoing pharmaceutical partnering discussions.
About ProMIS Neurosciences, Inc.(ARFXF)
ProMIS Neurosciences, Inc. (ARFXF) is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
Company documents relating to the fiscal year 2018 annual report and fiscal year 2019 quarterly reports can be viewed on the System for Electronic Document Analysis and Retrieval (SEDAR) at the link below:
https://www.sedar.com/search/search_en.htm
Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn
Fidelity is offering 40%+ interest on loans of MRKR shares.
I agree. RVX to this point has been somewhat more volatile than AMRN...although lately not so much. Stuck in the doldrums for a while now.
So IPIX finally gets a deal and the heat is off for now regarding the company's ability to survive. What happens? Stock pops then drops below where it was before the deal.
This would be a good week to start the run up to results.
FYI. There was too much fine print for me to loan out my shares
Poof. It is 2007 again, only this time the IP belongs to Theracour, not NNVC.
---------------------
NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials
PR NEWSWIRE 6:00 AM ET 8/5/2019
Yikes. The stock still exists?
I like the trend
Love the slow climb. An IND meeting can't be too far out....can it? Still trading only about $50k per day though. Would love to see a pop that doubles it...
yes, it does seem that way. still, it is far better than no deal...
Will look to buy nearer the NDA announcement
dumped a bunch of 'em at the open. hold only 1k now
Perhaps. My position is still relatively small
I recently doubled but could not resist some of those 16's today so I added another 15k.
This could be acquired for a few bucks....
Right now looks like a good time to add....so I did.
Wow. Amateur17 you are spot on with this one. I can't explain it, but I'm a believer.